Evidence map›Paper›PMID 38513623›Full record

ReviewDigestive diseases (Basel, Switzerland)2024

Proton Pump Inhibitors: Rational Use and Use-Reduction - The Windsor Workshop.

Peter Kahrilas, Foteini Anastasiou, Albert J Bredenoord, Hashem B El Serag, Joachim Labenz, Juan Mendive, Edoardo V Savarino, Daniel Sifrim, Mihaela Udrescu, Rena Yadlapati and 1 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Digestive diseases (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 6 countries.

Peter KahrilasDivision of Gastroenterology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Foteini Anastasiou4th Local Primary Care Team, Municipality Practice and Academic Practice of Heraklion, Crete, Greece.
Albert J BredenoordDepartment of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Hashem B El SeragDepartment of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Joachim LabenzDepartment of Internal Medicine, Jung-Stilling-Hospital, Siegen, Germany.
Juan MendiveLa Mina Primary Care Academic Centre, Catalan Health Institute, University of Barcelona, Barcelona, Spain.
Edoardo V SavarinoDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Daniel SifrimWingate Institute of Neurogastroenterology, Queen Mary University of London, London, UK.
Mihaela UdrescuIndividual Family Practice, Bucharest, Romania.
Rena YadlapatiDivision of Gastroenterology, University of California San Diego, La Jolla, California, USA.
A Pali HunginFaculty of Medical Sciences, Professor Emeritus, Primary Care and General Practice, Newcastle University, Newcastle upon Tyne, UK.
Amsterdam University Medical Centers · NLBaylor College of Medicine · USNorthwestern University · USQueen Mary University of London · GBScience and Technology Park of Crete · GRUniversitat de Barcelona · ESUniversity of California, San Diego · USUniversity of Padua · IT

Funding

The MVP Trial: A Randomized Controlled Trial of Mechanism Guided vs PPI Strategy for Laryngopharyngeal RefluxR01DK139089 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Rena Hiren Yadlapati · 2024 to 2026
$2.0M
Mechanism Guided Therapy for Laryngopharyngeal RefluxK23DK125266 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YADLAPATI, RENA HIREN · 2021 to 2025
$963k
NIDDK NIH HHS K23 DK125266NIDDK NIH HHS R01 DK139089
6 · The paper itself

Abstract

backgroundDespite deprescribing initiatives to curb overutilization of proton pump inhibitors (PPIs), achieving meaningful reductions in PPI use is proving a challenge. SUMMARY: An international group of primary care doctors and gastroenterologists examined the literature surrounding PPI use and use-reduction to clarify: (i) what constitutes rational PPI prescribing; (ii) when and in whom PPI use-reduction should be attempted; and (iii) what strategies to use when attempting PPI use-reduction. KEY MESSAGES: Before starting a PPI for reflux-like symptoms, patients should be educated on potential causes and alternative approaches including dietary and lifestyle modification, weight loss, and relaxation strategies. When commencing a PPI, patients should understand the reason for treatment, planned duration, and review date. PPI use at hospital discharge should not be continued without a recognized indication for long-term treatment. Long-term PPI therapy should be reviewed at least annually. PPI use-reduction should be based on the lack of a rational indication for long-term PPI use, not concern for PPI-associated adverse events. PPI use-reduction strategies involving switching to on-demand PPI or dose tapering, with rescue therapy for rebound symptoms, are more likely to succeed than abrupt cessation.

Indexed as

Proton Pump InhibitorsGastroesophageal RefluxHumansProton Pump InhibitorsGastroesophageal reflux diseaseOesophagusProton pump inhibitors

Identifiers

PMID38513623
PMCPMC11152023
OpenAlexW4394741117

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.